18/07/2025
July 18, 2025, marks the 20th anniversary of the meeting presentation that changed the global management of wet age-related macular degeneration (AMD), preventing blindness in millions of patients and saving healthcare systems hundreds of billions of dollars worldwide.
Congratulations to Dr. Philip J. Rosenfeld and his research team, who presented his breakthrough therapy using Avastin (bevacizumab) injections into the eye of patients with wet AMD at the annual meeting of the American Society of Retinal Specialists (ASRS) in Montreal. This therapy continues to be used today as the cornerstone of treatment for wet AMD, diabetic retinopathy, retinal vein occlusions, and a wide range of retinal diseases.